Performing 2-stage procedures using articulating antibiotic cement spacers to eradicate infection while providing pain relief and maintaining function has become common among many surgeons. Despite the efficacy of antibiotic cement spacers in the treatment of infected total knee arthroplasty, questions remain regarding the dosing of the antibiotic cement.
S everal treatment options exist for management of an infected total knee arthroplasty (TKA). The decision of which treatment option to use is based on many factors, including the medical comorbidities of the patient, the virulence of the infective organism, and the local wound environment. To achieve eradication of the infection while providing pain relief and maintaining function, 2-stage procedures using articulating antibiotic cement spacers have become a commonly selected option by many surgeons.
In 1970, Buchholz and Engelbrecht 1 introduced the concept of combining antibiotic agents with acrylic bone cement to decrease infection rates in primary total joint arthroplasty procedures. In the late 1980s and early 1990s, several reports described the use of antibiotic cement spacers for the treatment of prosthetic infections; the antibiotic cement spacers help to maintain the joint space following component removal and serve as local antibiotic delivery systems for eradication of the infection. [2] [3] [4] [5] These antibiotic cement spacers have been shown to produce high local antibiotic levels that exceed the levels that can be achieved with parenteral or oral administration alone. [6] [7] [8] [9] [10] [11] Despite the efficacy of antibiotic cement spacers in the treatment of infected arthroplasties, no commonly accepted standard exists regarding the dosing of the antibiotic cement.
12- 14 The release of antibiotic agents from these cement spacers is a complex process that depends on many variables. Relevant factors that influence this elution include the chosen antibiotic, antibiotic concentration, presence of other antibiotics, cement porosity, and exposed surface area of antibiotic-cement spacer. 6, 10, [15] [16] [17] In the current study, the authors reviewed their experience with articulating antibiotic-impregnated spacers. Different antibiotic regimens and concentrations were used, and the effect of these differences on the eradication of infection was assessed.
Materials and Methods
Between January 1998 and December 2005, the adult reconstruction service at the authors' institution treated 95 infected TKAs with 2-stage reimplantation using articulating spacers. The articulating spacers were constructed using the previous femoral component, a new polyethylene insert, and antibioticimpregnated cement. The choice of cement varied by surgeon, but included Palacos (Heraeus, Werheim, Germany) or Simplex (Stryker, Kalamazoo, Michigan). The medical records, microbiology reports, and pathology reports were retrospectively reviewed after institutional review board approval was obtained. For inclusion in this investigation, both stages of the reimplantation had to be performed by a fellowship-trained adult reconstruction surgeon (T.L.B., K.A.G., S.T.L.) at the authors' institution. Nineteen patients did not meet this requirement and were excluded from the study.
To verify the diagnosis of infection, each case had to demonstrate: (1) positive aspiration or surgical cultures; (2) acute inflammation on histopathologic evaluation of intra-articular tissue; or (3) an open wound with exposed hardware. In the records of 5 patients, none of these infection criteria could be definitively confirmed, and these patients were excluded. Of the remaining cases, each was reviewed to ensure that the constructed spacer contained antibiotics to which the causative organism was adequately susceptible. This was not the case for 2 patients, and these cases were excluded as well. This resulted in 69 knees available for inclusion.
The patients were then divided into groups by the antibiotic agents used and the amount of antibiotics added to the cement (Table 1 ). Four grams of total incorporated antibiotic was used to differentiate between high-and low-dose groups, taking into account the studies and recommendations of previous authors and investigators. [18] [19] [20] [21] [22] [23] [24] The study group comprised 36 men and 33 women, with the right knee involved in 30 patients and the left knee in 39 patients. Average patient age for the study group was 69.1 years (range, 48-89 years). As part of the medical history review for each patient, particular emphasis was placed on discerning factors that could potentially impair the patients' immune function and adversely affect their ability to eradicate infection, including diabetes mellitus, autoimmune disorders, inflammatory arthropathies, immunosuppressive medications, and renal failure.
The surgical protocol entailed a 2-stage exchange with delayed reimplantation using articulating spacers, as described by previous authors. [18] [19] [20] [21] The first stage consisted of thorough irrigation and debridement, a complete synovectomy, and removal of the prosthetic components and cement. Intraoperative tissue samples were sent for culture and pathology review. For construction of the spacer, the femoral component was cleaned, autoclaved, and reinserted with either a new polyethylene insert or a new stemmed allpolyethylene tibial component ( Figure) . Powdered tobramycin, either alone or in combination with powdered vancomycin, was added to the acrylic bone cement before application to the nonarticulating surfaces of the implants. The different combinations of antibiotic agents are outlined in Table 1 . The temporary implants were then cemented in place using the poor cement technique to prevent optimal fixation and facilitate their removal at the definitive reimplantation procedure. Antibiotic choice for spacer incorporation varied by surgeon. One surgeon (T.L.B.) routinely used 2-agent spacers (vancomycin1tobramycin) for all cases but would increase the doses of both agents for infections known to be caused by more virulent organisms. The other 2 surgeons (K.A.G., S.T.L.) usually used 1-agent spacers (tobramycin); however, 1 surgeon (S.T.L.) would add vancomycin if sensitivity of the organism to tobramycin was not known or questionable, whereas the other surgeon (K.A.G.) would add vancomycin only for those cases in which the organism was known preoperatively to not be susceptible to tobramycin. For this investigation, satisfactory susceptibility of the isolated organisms to the incorporated antibiotics was retrospectively confirmed for each case.
After curing the antibiotic-cement spacer, routine layered wound closure was performed, and the operative leg was placed in a bulky dressing. No drains were used. Postoperatively, the patients were allowed partial weight bearing on the affected leg using a walker or crutches to assist with ambulation, and range of motion exercises were begun under the direction of a physical therapist. All patients received at least 6 weeks of intravenous antibiotics supervised by the infectious disease service and had an antibiotic-free period of at least 2 weeks prior to reimplantation.
On average, reimplantation occurred 126 days (range, 71-288 days) after the initial debridement and spacer placement. Three knees showed signs of recurrence prior to reimplantation and were considered failures of the protocol. All patients were followed at regular intervals with clinical examinations and radiographs for possible recurrence. Average follow-up was 31 months (range, 6-70 months).
Chi-square test or Fisher's exact test was used when appropriate, and observations with a P value of .05 or less were considered significant.
results
Successful infection eradication was accomplished in 61 (88.4%) of 69 knees. Of the 8 failures, 3 presented with clinical signs of recurrent infection prior to attempted reimplantation. Two failures were diagnosed at the time of reimplantation when intraoperative frozen sections were positive for acute inflammation demonstrating more than 10 neutrophils per high-powered field. The remaining 3 treatment failures were diagnosed at 2, 12, and 18 months postoperatively. Of the 8 treatment failures, 6 underwent additional surgical procedures. Two patients were managed with another articulating spacer, 3 underwent resection arthroplasty, and 1 underwent above-knee amputation. Two patients were managed nonoperatively with chronic antibiotic suppression.
Medical comorbidities that impaired immune function were frequently encountered in this study group; 31 (44.9%) patients were found to have coexisting factors. Comorbidities were less prevalent in the patients who received 1-agent spacers (9 of 33 patients; 27.3%) compared with those who recieved 2-agent spacers (22 of 36 patients; 61.1%) (P5.003). Differences in patient immune status were not seen between the high-and low-dose subgroups for either the 1-or 2-agent spacer groups ( Table 2) .
As shown in Table 3 , eight total treatment failures occurred (11.6%). Four (12%) treatment failures were observed in 33 knees in the 1-agent spacer group, and 4 (11%) treatment failures were noted in 36 knees in the 2-agent spacer group despite the greater percentage of patients having impaired immune function. When the groups were assessed relative to high or low doses of antibiotics incorporated into the antibiotic cement, statistical differences in failure rates were not detected. For the low-dose, 1-agent spacer subgroup, 3 failures were observed occurring in 18 (17%) knees. All 3 of these failures occurred in patients with no apparent impairment to immune function. For the high-dose 1-agent spacer subgroup, 1 (7%) treatment failure was noted in 15 knees. This patient had impaired immune function. For the high-dose 2-agent spacer subgroup, 4 (18%) failures were observed in 22 cases. Three of these failures occurred in patients with impaired immune function. No treatment failures were seen in the low-dose, 2-agent spacer subgroup.
To elucidate whether the immune status of study patients played a role in successful eradication, Table 4 stratifies the success rate of the immune-impaired subset of this study group. Differences in success rates in the immune-impaired population were not detectable between the 1-and 2-agent spacers, nor between low-and high-dose subgroups.
One or more infecting organisms were identified in 61 (88.4%) of 69 knees. Table  5 lists the organisms and the frequency with which each was encountered. The most frequently encountered organism was coagulase-negative Staphylococcus, which was isolated from 20 (32.8%) of 61 knees with positive cultures. Methicillin-resistant Staphylococcus was more frequently encountered in the later years of the study period and was isolated from 8 (13.1%) of the 61 culture-positive knees. Multiple organisms were identified in 1 knee. For 8 of the patients, culture results remained negative, and these cases were included based on their ability to fulfill the other infection criteria previously mentioned. The majority (5 of 8) of these culture-negative patients were referred from outside surgeons or institutions and had been taking oral or intravenous antibiotics at presentation. Treatment for these patients varied depending on surgeon preference, with half receiving 2-agent spacers and half receiving 1-agent spacers. No treatment failures occurred within this small subset of patients. 
discussion
The addition of antibiotic agents to acrylic bone cement has proven to be a valuable adjunct in the management of infected TKAs. Suitable antibiotics must be heat stable to maintain bioactivity and water soluble to allow effective elution from the cement to the surrounding tissues. The process of antibiotic elution from antibiotic-cement spacers is dependent on many variables and is not completely understood.
6,10,12,15-17 Currently, no commonly accepted standard exists regarding the appropriate dosing of antibiotic cement.
12-14,25
The capacity of antibiotic-impregnated cement to produce high local antibiotic levels has been noted by other investigators. [6] [7] [8] [9] [10] This effective release of the agent from the cement to the surrounding tissues is a nonlinear, time-dependent process. The highest rates of antibiotic elution occur in the first 18 to 24 hours after spacer placement, with a sustained lower level of release and then continuing for weeks to months. 15, [26] [27] [28] [29] The use of deep surgical drains for the first 24 to 48 postoperative hours serves to evacuate the joint during the time of maximal antibiotic release and is probably counterproductive. The ability of an antibiotic agent to eradicate infection is thought to be dose dependent. Spacers with higher concentrations of added antibiotics produce higher local antibiotic levels and achieve longer durations of elution.
12,30 When reviewing the failures of the 1-agent spacers in the current study, the authors failed to observe a dose-dependent statistical difference, but the rate of treatment failure trended higher for the low-dose subgroup, and these failures tended to occur in patients with normal immune function. Although rare complications have been reported with the use of high-dose spacers, their overall safety is supported by several investigations. 12, 22, 31, 32 The current authors encountered no apparent adverse effects related to the higher antibiotic doses in this study.
The results of studies that have investigated the elution of combined antibiotic agents from bone cement have been inconsistent. Both synergistic and antagonistic effects have been described when more than 1 antibiotic is incorporated. Penner et al 33 reported that tobramycin and vancomycin eluted more effectively from cement when used together. This apparent antibiotic synergism is supported by the findings of other investigators. 30 However, other authors have noted that combining antibiotic agents may produce a decrease in the successful elution of agents from the cement. 34, 35 In the current study, the high-dose 2-agent spacers had an increased failure rate compared with their low-dose counterparts. This increased rate of failure in the high-dose 2-agent subgroup may indicate an antagonistic effect on the elution of the 2 agents, or it may simply be related to the selection of the higher dose regimen for infections known to be caused by more resistant organisms.
Limitations of this study included its retrospective nature, its relatively small sample size, the bias toward certain antibiotic regimens when more virulent organisms were encountered, and the inability to assess and compare the quality of surgical debridement.
For infections caused by more virulent organisms, those for which the infective organism is not known preoperatively, and those in immune-compromised patients, the authors recommend that 2-agent spacers be chosen. The authors found comparable rates of eradication using these spacers although the patients who received them were more likely to have 1 or more factors that served to impair their immune function. Further inquiry into the optimal combinations and concentrations of antibiotic agents incorporated into these spacers is needed to help minimize treatment failures while maintaining maximal patient safety. 
